Deals in Depth: March 2009
Executive SummaryOur monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries. March 2009 dealmaking highlights: BMS' worldwide ex-Japanese license to Nissan/Teijin's CV candidate NTC801 topped the alliance list in terms of potential deal value at $210mm. The remaining pharma alliances for March didn't even surpass $50mm in pre-commercial value. In M&As, the Big Pharma mega merger of Merck and Schering-Plough was the biggest news, in a deal valued around $42bn. Pharmaceutical financings were down by about $100mm compared with February, and Early VC rounds made up the majority of the $406mm raised. Funding for device firms, on the other hand, was up from last month to $297mm thanks to a strong showing of late venture financings.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.